New York, May 20, 2026, 16:03 EDT
Esperion Therapeutics shares stayed flat at $3.13 late Wednesday, just under Archimed’s $3.16-a-share cash offer. Investors are looking at what’s left in the take-private deal and the open milestone risks. The stock moved in a tight range from $3.13 to $3.14, with volume topping 7 million shares.
Esperion isn’t just a small-cap drug name trading on growth anymore. Now it’s more of a merger spread play, with shares moving on the gap between the deal price and where it trades. The spread’s slim, but still there.
Archimed said May 1 it will buy the Ann Arbor, Michigan-based firm for up to about $1.1 billion. The deal includes $3.16 per share in cash and a non-tradeable contingent value right, or CVR, tied to future sales targets. Esperion CEO Sheldon Koenig called the transaction an “exciting new chapter” and said shareholders get “attractive and immediate upfront value.” Archimed partner Justin Bateman said the target has a “strong foundation” in cardiovascular and primary-care. Esperion Therapeutics, Inc.
The CVR holds most of the upside left. Esperion shareholders could get up to $100 million in total if bempedoic-acid sales in the U.S. top the required levels in 2027 and if Enbumyst, a bumetanide nasal spray, meets a different sales bar by 2030. Cantor’s Kristen Kluska told Reuters the price looked low versus her outlook for Esperion’s peak U.S. sales.
Esperion’s newest quarterly filing puts the deal in context. First-quarter revenue came in at $80.1 million, up from $65.0 million last year. Net loss was $25.2 million, less than the $40.5 million loss a year ago. Product sales totaled $43.4 million, with $36.7 million from collaboration revenue.
Esperion’s next big update is clinical, not tied to financials. The company said it will present two new and three encore abstracts on bempedoic acid at the European Atherosclerosis Society Congress, set for May 24-27 in Athens. Koenig said the data will show the drug’s “breadth and durability.” That includes results from pediatric Phase 2 trials and analysis of patients with LDL-C, or “bad” cholesterol, cut by at least 30%. Esperion Therapeutics, Inc.
Competition is still tough. Esperion’s annual report names generic statins, ezetimibe, Amgen’s Repatha, Regeneron and Sanofi’s Praluent, and Novartis’ Leqvio as rivals for bempedoic acid and the bempedoic acid-ezetimibe combo pill. That’s important because the CVR payout is tied to future net sales, not just the closing of the deal.
Still, Esperion is telling investors the deal isn’t done yet. The company said the merger has to get shareholder signoff and clear regulators. If that doesn’t happen or gets held up, Esperion warned the stock could drop from where it’s trading now, since prices factor in the merger closing. According to the filing, anyone holding CVRs could also get nothing if the milestones aren’t achieved.
Markets didn’t move Esperion much. Wall Street traded higher Wednesday with chip stocks ahead of Nvidia’s numbers, and the Nasdaq Composite rose more than 1% in the afternoon. Normally a tape like that would push risk names, but Esperion was pinned by its merger details.
Nasdaq trades from 9:30 a.m. to 4:00 p.m. ET in its regular session, with after-hours going to 8:00 p.m. ET. For 2026, the next U.S. market holiday is Memorial Day on May 25, according to its posted calendar. The market will be open Wednesday.
